Coya shares sink on Phase 2 Alzheimer's data for deprioritized drug

Coya Therapeutics’ stock price {$COYA} fell more than 20% on Tuesday after the company reported Phase 2 data for its Alzheimer’s disease program, called COYA 301. Though Coya de-emphasized COYA 301 as part of ...